Fda approves a treatment option for patients with her2-positive metastatic breast cancer

Fda approves first new drug under international collaboration, a treatment option for patients with her2-positive metastatic breast cancer.fda - as part of project orbis, granted approval of tukysa to seattle genetics.
SGEN Ratings Summary
SGEN Quant Ranking